Ozempic babies: real fertility effect or viral panic?

What did @todayshow actually say?

Dr. Tara Narula laid out three distinct mechanisms for what's being called the "Ozempic baby" phenomenon: GLP-1 drugs may improve fertility by promoting weight loss in people with obesity or PCOS, they may reduce oral contraceptive absorption by slowing gastric motility, and vomiting or diarrhea caused by the drugs can further cut absorption. She also flagged a two-month washout recommendation before pregnancy. This wasn't fear-mongering. It was a structured, mechanism-based explanation that largely reflects what's in the current literature, delivered with appropriate caution about the gaps in long-term data.

Does the science back this up?

Mostly, yes, though the evidence is stronger for some claims than others. The fertility-via-weight-loss link is well-established. The oral contraceptive absorption concern is biologically plausible but not yet confirmed in clinical pregnancy outcome data.

On the fertility side: obesity and PCOS are both associated with anovulation and reduced fertility, and weight loss does restore ovulatory function. A 2023 review in Obesity Reviews (Joham et al.) confirmed that weight reduction in PCOS patients improves menstrual regularity and ovulation rates. This part of Narula's claim is solid.

On absorption: semaglutide delays gastric emptying, which is its primary mechanism for reducing post-meal glucose spikes. Novo Nordisk's own prescribing information for Ozempic notes that drugs with narrow therapeutic windows should be monitored when co-administered. However, a 2023 pharmacokinetic study published in Clinical Pharmacokinetics (Overgaard et al.) found that semaglutide did not meaningfully alter levonorgestrel or ethinyl estradiol exposure in healthy volunteers. That's an inconvenient finding for the absorption narrative, and Narula didn't mention it.

What did they get wrong (or right)?

Narula gets credit for not overselling this. She explicitly said "the message is not this is a fertility drug," which is the right framing. She also correctly identified that preconception metabolic optimization matters for outcomes like gestational diabetes and preeclampsia.

Where the segment falls short: the absorption claim was presented with more confidence than the data supports. The Overgaard 2023 pharmacokinetic trial is the most relevant study, and it did not find significant changes in oral contraceptive bioavailability with semaglutide. That doesn't mean the risk is zero, it means the mechanism Narula described doesn't appear to translate into measurable absorption problems in controlled settings.

The vomiting and diarrhea point is fair as a general principle. Severe GI symptoms can reduce absorption of any oral medication. But framing this as a distinct, additive pregnancy risk mechanism without data on actual pregnancy rates adds heat without light.

The "two months in advance" washout recommendation is consistent with Novo Nordisk's guidance for Wegovy, based on semaglutide's approximately five-week half-life. That's accurate. The admission that solid clinical data won't arrive for another five to seven years is also refreshingly honest.

What should you actually know?

If you are taking a GLP-1 drug and using oral contraceptives, here is what is actually known. Weight loss from GLP-1 therapy can restore ovulation in people who had suppressed cycles due to obesity or PCOS. This is real and clinically documented. If your periods were irregular before starting the drug and become regular on it, your contraceptive needs may have changed regardless of any absorption question.

The absorption concern exists as a theoretical mechanism but lacks clinical confirmation in pharmacokinetic studies specifically designed to test it. The FDA and Novo Nordisk both recommend using backup contraception or alternative methods, which is conservative but reasonable given the stakes.

Anyone planning a pregnancy while on a GLP-1 drug should know the current FDA labeling recommends discontinuing semaglutide at least two months before a planned pregnancy. The drug's long half-life is the reason. There are no large human trials on GLP-1 exposure in early pregnancy, only animal data showing fetal harm at high doses. Until the registry studies report out, caution is warranted.

• Restored ovulation due to weight loss is the most evidence-supported pregnancy risk mechanism.
• Oral contraceptive absorption interference is theoretically plausible but not confirmed by pharmacokinetic studies.
• Backup contraception is recommended by manufacturers during GLP-1 use regardless of which mechanism is at play.
• Discontinue GLP-1 drugs at least two months before a planned pregnancy per current labeling guidance.